0.018
0.00 (0.00%)
| Previous Close | 0.018 |
| Open | 0.018 |
| Volume | 10,000 |
| Avg. Volume (3M) | 211,811 |
| Market Cap | 15,983,261 |
| Price / Sales | 1.99 |
| Price / Book | 4.30 |
| 52 Weeks Range | |
| Earnings Date | 23 Aug 2024 |
| Profit Margin | -138.79% |
| Operating Margin (TTM) | -96.82% |
| Diluted EPS (TTM) | -0.010 |
| Quarterly Revenue Growth (YOY) | 39.00% |
| Total Debt/Equity (MRQ) | 140.10% |
| Current Ratio (MRQ) | 0.780 |
| Operating Cash Flow (TTM) | -5.57 M |
| Levered Free Cash Flow (TTM) | -3.84 M |
| Return on Assets (TTM) | -30.36% |
| Return on Equity (TTM) | -173.93% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (SG) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | IX Biopharma | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | 0.13 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| IX BIOPHARMA | 16 M | - | - | 4.30 |
| TJ DARENTANG USD | 3 B | 52.24% | 5.44 | 1.65 |
|
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 50.56% |
| % Held by Institutions | 0.09% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Lee (Yip Hang Eddy) | 04 Sep 2024 | 217,000,852 (24.57%) |
| HRT Corporation Pte. Ltd. | 04 Sep 2024 | 66,748,029 (7.56%) |
| Tang (Choy Leng Jane) | 04 Sep 2024 | 22,793,565 (2.58%) |
| Narulla (Jaspal Singh) | 04 Sep 2024 | 20,727,047 (2.35%) |
| Tan (See Tee) | 04 Sep 2024 | 17,470,800 (1.98%) |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 23 May 2025 | Announcement | General Announcement::Notice of End of Conversion Period and Maturity Date of Convertible Bonds |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |